Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to 357.38%.

  • Stoke Therapeutics' EBITDA Margin rose 1789700.0% to 357.38% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.86%, marking a year-over-year increase of 6478500.0%. This contributed to the annual value of 243.76% for FY2024, which is 9356000.0% up from last year.
  • Stoke Therapeutics' EBITDA Margin amounted to 357.38% in Q3 2025, which was up 1789700.0% from 168.51% recorded in Q2 2025.
  • Stoke Therapeutics' 5-year EBITDA Margin high stood at 71.22% for Q1 2025, and its period low was 1226.72% during Q2 2023.
  • In the last 4 years, Stoke Therapeutics' EBITDA Margin had a median value of 625.0% in 2024 and averaged 589.62%.
  • Per our database at Business Quant, Stoke Therapeutics' EBITDA Margin crashed by -4454200bps in 2023 and then surged by 9099600bps in 2024.
  • Quarter analysis of 4 years shows Stoke Therapeutics' EBITDA Margin stood at 768.88% in 2022, then fell by -25bps to 957.71% in 2023, then surged by 95bps to 47.75% in 2024, then crashed by -648bps to 357.38% in 2025.
  • Its EBITDA Margin stands at 357.38% for Q3 2025, versus 168.51% for Q2 2025 and 71.22% for Q1 2025.